


23. Day CP. Non-alcoholic steatohepatitis: where are we now and where are we going? Gut 2002;5:585-588.


33. Stewart SF, Leathart JB, Chen Y, Daly AK, Rolla R, Vay D, Mottaran E, Vidal M, Albano E, Day CP. The valine-alanine manganese superoxide dismutase polymorphism is not associated with increased oxidative stress or susceptibility to advanced alcoholic liver disease. Hepatology 2002;36:1355-60.


58. Day CP. Genes or environment to determine ALD and NAFLD. Liver International. 2006;26:1021-28


62. Daly AK, Aithal GP, Leathart JBS, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8 and ABCC2 genotypes. Gastroenterology 2007;132:272-281.


73. Newton JL, Jones DEJ, Henderson E, Kane L, Wilton K, Burt AD, Day CP. Fatigue in Non-Alcoholic Fatty Liver Disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 2008; 57:807-13


97. Day CP. Genetic and environmental susceptibility to non-alcoholic fatty liver disease. Digestive Diseases 2010;28:255-60.


102. Kendrick SFW, Day CP. Can pentoxifylline secure its place in liver therapeutics?. Nat Rev Gastro Hep 2010;7:593-4

103. Seth D, Daly AK, Haber PS, Day CP. A case in point: Genetic similarities in alcoholic and non-alcoholic liver disease. Hepatology 2010;51:1463-5.


